During the past decade, Indiana Oncology Hematology Consultants conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 11 clinical trials were completed, i.e. on average, 550% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Indiana Oncology Hematology Consultants" #1 sponsor was "Hoosier Cancer Research Network" with 4 trials, followed by "Point Therapeutics" with 4 trials sponsored, "Bristol-Myers Squibb" with 3 trials sponsored, "Genentech, Inc." with 2 trials sponsored and "Puma Biotechnology, Inc." with 2 trials sponsored. Other sponsors include 11 different institutions and companies that sponsored additional 21 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Indiana Oncology Hematology Consultants" #1 collaborator was "Pfizer" with 2 trials as a collaborator, "Astex Pharmaceuticals, Inc." with 1 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "Bayer" with 1 trials as a collaborator and "Bristol-Myers Squibb" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Indiana Oncology Hematology Consultants" are "Breast Cancer" (5 trials), "Melanoma" (4 trials), "Acute Myeloid Leukemia" (3 trials), "Pancreatic Cancer" (3 trials) and "Adenocarcinoma" (2 trials). Many other conditions were trialed in "Indiana Oncology Hematology Consultants" in a lesser frequency.

Most popular intervention types in "Indiana Oncology Hematology Consultants" are "Drug" (30 trials), "Biological" (2 trials), "Other" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Dexamethasone" (2 trials), "Docetaxel" (2 trials), "Everolimus" (2 trials) and "Exemestane" (2 trials). Other intervention names were less common.

The vast majority of trials in "Indiana Oncology Hematology Consultants" are 24 trials for "All" genders, 6 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Indiana Oncology Hematology Consultants". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 23 completed trials in Indiana Oncology Hematology Consultants, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Indiana Oncology Hematology Consultants, 2 "Phase 1" clinical trials were conducted, 19 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".